Filing Details
- Accession Number:
- 0001437749-19-007119
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-04-12 18:04:57
- Reporting Period:
- 2019-04-11
- Accepted Time:
- 2019-04-12 18:04:57
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
72444 | Vaxart Inc. | VXRT | Biological Products, (No Disgnostic Substances) (2836) | 591212264 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1652204 | Sean Tucker | C/O Vaxart, Inc. 290 Utah Ave. Suite 200 South San Francisco CA 94080 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2019-04-11 | 27,273 | $1.10 | 52,661 | No | 4 | P | Indirect | By joint tenancy with Frances Chang and Sean Tucker |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | By joint tenancy with Frances Chang and Sean Tucker |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Common Stock Warrant (right to buy) | Acquisiton | 2019-04-11 | 27,273 | $1.10 | 27,273 | $1.10 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
27,273 | 2019-04-11 | 2024-04-11 | No | 4 | P | Indirect |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 47,653 | Direct | |
Common Stock | 9,060 | Indirect | By spouse |
Footnotes
- Each share of common stock was purchased together with a common warrant to purchase one share of the Issuer's common stock at the combined purchase price of $1.10. The Reporting person may not exercise any portion of the common warrant to the extent that he would beneficially own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days' prior notice from the Reporting Person to the Issuer, he may increase the amount of beneficial ownership of outstanding stock after exercising his common warrants up to 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the common warrants.